By: Staff Writer
June 16, Colombo (LNW): Sri Lanka’s pharmaceutical regulatory environment is facing increasing scrutiny as concerns mount over pricing policies, regulatory delays, and their potential impact on medicine availability.
Industry representatives claim that a combination of prolonged approval procedures and aggressive pricing expectations has created significant obstacles for international pharmaceutical suppliers, particularly companies from India, which remains one of Sri Lanka’s largest sources of medicines.
The controversy revolves around the National Medicines Regulatory Authority’s handling of medicine registrations and import licences. Pharmaceutical companies allege that regulators are seeking reductions in the Maximum Retail Price of products, even when those medicines are not included in the country’s official list of price-controlled drugs.
According to industry sources, there is uncertainty regarding the criteria used to determine acceptable prices. In some cases, comparisons are reportedly made with prices in India, while in others, locally manufactured alternatives are used as benchmarks. Suppliers argue that neither comparison accurately reflects the economic realities of importing medicines into Sri Lanka.
Manufacturers point to a range of expenses that influence pricing, including international logistics, regulatory compliance, product registration requirements, labeling obligations, and financing costs. They also note that currency movements and import-related risks have increased operating expenses over recent years.
The dispute has reignited debate over the effectiveness of Sri Lanka’s medicine pricing framework. Experts note that drug pricing serves multiple public policy objectives, including ensuring affordability, protecting patients, maintaining supply chains, and encouraging investment in pharmaceutical manufacturing.
Globally, many countries adopt targeted pricing controls focused on essential medicines while allowing market forces to determine prices for other categories. Industry representatives argue that such systems provide predictability and help sustain long-term supply.
Critics of the current Sri Lankan approach contend that excessive intervention may discourage reputable manufacturers from remaining in the market. They point to reports that several internationally recognized pharmaceutical brands have either reduced their presence or withdrawn products over time.
Regulatory procedures have also come under examination. Companies cite requirements such as bio-equivalence studies, facility inspections, and extensive stability testing, which can increase costs and lengthen approval timelines. Some suppliers report that introducing a new medicine into Sri Lanka can take several years.
Another area of concern is the application of a “need clause,” under which authorities may reject registrations if a medicine is deemed unnecessary for the local market. Industry participants argue that such decisions can create additional uncertainty for investors and manufacturers.
The most urgent challenge remains the backlog of more than 1,000 pending import licences. Pharmaceutical companies warn that prolonged delays could affect product availability and disrupt supply chains if unresolved.
As policymakers seek to balance affordability with access, the debate highlights a difficult question facing Sri Lanka’s healthcare sector: how to regulate medicine prices without undermining the incentives needed to ensure a stable and reliable supply of essential drugs.